Tumour seeding of the renal tumour biopsy tract – a histologically under‐recognised feature?

2020 ◽  
Vol 76 (5) ◽  
pp. 763-766
Author(s):  
Philip S Macklin ◽  
Clare L Verrill ◽  
Ian S D Roberts ◽  
Richard Colling ◽  
Mark E Sullivan ◽  
...  
2019 ◽  
Vol 18 (1) ◽  
pp. e158
Author(s):  
M.E. Sullivan ◽  
P. Macklin ◽  
R. Tapping ◽  
G. Webster ◽  
I. Roberts ◽  
...  

2019 ◽  
Vol 75 (5) ◽  
pp. 861-867 ◽  
Author(s):  
Philip S. Macklin ◽  
Mark E. Sullivan ◽  
Charles R. Tapping ◽  
David W. Cranston ◽  
Guy M. Webster ◽  
...  

2019 ◽  
Vol 201 (Supplement 4) ◽  
Author(s):  
Philip Macklin ◽  
Mark Sullivan* ◽  
Charles Tapping ◽  
David Cranston ◽  
Guy Webster ◽  
...  

2016 ◽  
Vol 69 (4) ◽  
pp. 674-675 ◽  
Author(s):  
Roger Kockelbergh ◽  
Leyshon Griffiths

2017 ◽  
Vol 197 (4S) ◽  
Author(s):  
Patrick O. Richard ◽  
Lisa Martin ◽  
Luke Lavallée ◽  
Phil Violette ◽  
Maria Komisarenko ◽  
...  

2018 ◽  
Vol 12 (8) ◽  
Author(s):  
Patrick O. Richard ◽  
Lisa Martin ◽  
Luke T. Lavallée ◽  
Philippe D. Violette ◽  
Maria Komisarenko ◽  
...  

Introduction: Renal tumour biopsies (RTBs) can provide the histology of small renal masses (SRMs) prior to treatment decisionmaking. However, many urologists are reluctant to use RTB as a standard of care. This study characterizes the current use of RTB in the management of SRMs and identifies barriers to a more widespread adoption.Methods: A web-based survey was sent to members of the Canadian and Quebec Urological Associations who had registered email address (n=767) in June 2016. The survey examined physicians’ practice patterns, RTB use, and potential barriers to RTB. Chi-squared tests were used to assess for differences between respondents.Results: The response rate was 29% (n=223), of which 188 respondents were eligible. A minority of respondents (12%) perform RTB in >75% of cases, while 53% never perform or perform RTB in <25% of cases. Respondents with urological oncology fellowship training were more likely to request a biopsy than their colleagues without such training. The most frequent management-related reason for not using routine RTB was a belief that biopsy won’t alter management, while the most frequent pathology-related reason was the risk of obtaining a false-negative or a non-diagnostic biopsy.Conclusions: Adoption of RTBs remains low in Canada. Concerns about the accuracy of RTB and its ability to change clinical practice are the largest barriers to adoption. A knowledge translation strategy is needed to address these concerns. Future studies are also required in order to define where RTB is most valuable and how to best to implement it.


Sign in / Sign up

Export Citation Format

Share Document